About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Infusion System for Hepatic Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNANCT04684862

Infusion System for Hepatic Cancer

This is a single-site, open-label continued access study/treatment protocol under a treatment IDE. In addition to treating patients, the primary objective of this study is to assess the safety of usin...

Lead sponsor: Ronald DeMatteo, M.D.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Ronald DeMatteo, M.D.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients must be greater than or equal to 18 years of age
•Have a clinical or biopsy-proven diagnosis of colorectal cancer metastatic to liver or intrahepatic cholangiocarcinoma
•At the time of pump placement, patients will either have unresectable, chemotherapy-responsive disease or they will be undergoing resection with planned postoperative HAI
•Be deemed appropriate for pump chemotherapy by both a medical oncologist and a surgical oncologist
•Provision of signed and dated informed consent form

Exclusion Criteria

•Known active infection
•Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the trial

Related studies

RECRUITINGPhase 1

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

NCT06058663 · Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, and more

RECRUITINGPhase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

NCT06728410 · Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, and more

RECRUITINGPhase 2

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

NCT04891289 · Intrahepatic Cholangiocarcinoma

RECRUITINGPhase 2

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)

NCT06313203 · Intrahepatic Cholangiocarcinoma, Chemotherapy Effect

Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers

NCT07337850 · Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 15, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhaseNA

Enrollment100

Start dateFeb 2021

Last updatedDec 15, 2025

Condition

Colorectal Cancer Metastatic to Liver Intrahepatic Cholangiocarcinoma

Locations shown

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions